ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-0-0-09930 10.3892/etm.2021.9930 Review MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review) ZhouKun 1 ChangYinxia 2 HanBo 3 LiRui 2 WeiYanming 2 Shanxi Institute of Energy, Taiyuan, Shanxi 030600, P.R. China College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, P.R. China College of Basic Medicine, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, P.R. China Correspondence to: Dr Yanming Wei, College of Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, No. 121, DaXue Street, Jinzhong, Shanxi 030619, P.R. China weiyanming2005@aliyun.com

Abbreviations: Hsp70, heat shock protein 70; VEGF, vascular endothelial growth factor; AKT, protein kinase B; AGO, argonaute protein; Mcl-1, myeloid cell leukemia-1; NF-κB, nuclear factor kappa-B; PI3K, phosphatidylinositol 3 kinase; ERK, extracellular regulated protein kinase; mTOR, mammalian target of rapamycin; Cav-1, caveolin-1; PTEN, phosphatase and tensin homolog; MAPK, mitogen-activated protein kinase; TLR, Toll-like receptor; LPS, lipopolysaccharide; SHIP-1, Src homology 2-containing inositol phosphatase-1; SCI, spinal cord injury; SLE, systemic lupus erythematosus; TGF-β, transforming growth factor-β; DKD, diabetic kidney disease; Treg, regulatory T cells; ITGA5, integrin subunit α 5; AhR, aryl hydrocarbon receptor; EZH2, enhancer of zeste homolog 2

 05 2021 17 03 2021 21 5 499 06 10 2020 18 02 2021 Copyright: © Zhou et al. 2021 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Triptolide is the main bioactive constituent isolated from the Chinese herb Tripterygium wilfordii Hook F., which possesses a variety of pharmacological properties. MicroRNAs (miRNAs/miRs) are short non-coding RNAs that regulate gene expression post-transcriptionally. miRNAs are implicated in several intracellular processes, whereby their dysregulation contributes to pathogenesis of various diseases. Thus, miRNAs have great potential as biomarkers and therapeutic targets for diseases, and are implicated in drug treatment. Previous studies have reported that specific miRNAs are targeted, and their expression levels can be altered following exposure to triptolide. Thus, miRNAs are emerging as crucial mediators in the pharmacological activities of triptolide. The present review summarizes current literature on miRNAs as target molecules in the pharmacological activities of triptolide, including antitumor, anti-inflammatory, immunosuppressive, renal protective, cardioprotective, antiangiogenesis activities and multiorgan toxicity effects. In addition, the diverse signaling pathways involved are discussed to provide a comprehensive understanding of the underlying molecular mechanisms of triptolide in the regulation of target miRNAs.

 triptolide microRNAs antitumor anti-inflammatory immunosuppressive renal protective cardioprotective antiangiogenesis multiorgan toxicity Funding: The present review was supported by the Applied Basic Research Program of Science and Technology Department of Shanxi Province (grant no. 201801D121357), the Research Project of Shanxi Provincial Health and Family Planning Commission (grant no. 201601114) and the Research Fund from Shanxi Key Laboratory of Innovative Drug for Treatment of Serious Diseases Basing on the Chronic Inflammation (grant no. SXIDL-2018-08). 1. Introduction

Traditional Chinese medicine is attracting great interest due to the high efficacy of its biological components for the treatment of several diseases. For example, Astragalus membranaceus is commonly used in various herbal formulations to cure inflammatory diseases and cancers (1), and Forsythia suspense-based treatments have provided notable protection against bacterial infections, allergies, neurodegeneration and cancers (2). Triptolide, a diterpenoid triepoxide, is one of the main active ingredients extracted from the traditional Chinese herb, Tripterygium wilfordii Hook F., which possesses several pharmacological activities. In preclinical in vitro and in vivo models, triptolide has exhibited a broad spectrum of potent antitumor activity (3,4). Triptolide can induce cell cycle arrest, interfere with tumor cell proliferation, suppress cell migration, invasion and metastasis, prevent angiogenesis, enhance caspase-dependent and -independent cell death, and produce a synergistic effect in combination with antitumor drugs (3,5). In addition, triptolide significantly inhibits the expression of pro-inflammatory cytokines and chemokines, and is considered a promising anti-inflammatory agent for the treatment of diseases, including rheumatoid arthritis (6). Triptolide exhibits profound immunosuppressive activity by regulating the proportion of immune cells and inhibiting the release of immune factors (7). Triptolide also alleviates renal and myocardial pathological injuries, and exerts protective roles in kidney and cardiovascular diseases (8,9). However, despite its desirable clinical applications, treatment with triptolide is restricted due to its potential multiorgan toxicity, including hepatic, cardiac and reproductive toxicity (10).

Currently, the molecular mechanisms underlying the pharmacological activities of triptolide have been extensively investigated (11,12), which have revealed various cellular targets and the involvement of different signaling pathways, including the heat shock protein 70 (Hsp70), vascular endothelial growth factor (VEGF), c-Jun and protein kinase B (AKT) pathways (13). MicroRNAs (miRNAs/miRs) are highly conserved endogenous small non-coding RNA molecules that negatively regulate gene expression. The phylogenetic conservation of several miRNAs across mammals highlights the importance of the miRNAs regulatory network (14). Consistently, extensive studies of miRNA knockout and overexpression models have suggested that miRNAs participate in various essential cellular processes, including cell differentiation, organ development, metabolism and apoptosis (15,16). In addition, several diseases are associated with aberrant expression of miRNAs, and miRNAs exhibit potential as biomarkers and therapeutic targets for diseases, and are highly implicated in drug treatment (17). Increasing evidence suggest that miRNAs also serve as key regulatory elements for triptolide-mediated activity (18-22). Some studies assessing the effect of triptolide on miRNAs have demonstrated that the expression levels of specific miRNAs change several folds in different cell lines and tissues (23-25).

The present review summarizes miRNAs targeted by triptolide and discusses the underlying molecular mechanisms defining the association between the expression of miRNAs and triptolide to outline the critical roles these miRNAs play in the pharmacological activities of triptolide.

 2. An overview of miRNAs

miRNAs are single-stranded RNA molecules that are 22 nucleotides in length, and their genes mostly reside in either introns or exons of non-coding transcripts, while others are located within introns of neighboring protein-coding pre-mRNAs and dispersed across the genome (26). miRNA genes are transcribed in the nucleus by RNA polymerase II or III into long primary transcripts called pri-miRNA, which are folded into double-stranded RNA hairpin. The pri-miRNA is cleaved by a microprocessor to release the miRNA precursor named pre-miRNA, containing a stem-loop of ~60 nucleotides, which is subsequently exported to the cytoplasm by exportin 5 and Ran-GTP (15,27). In the cytoplasm, the pre-miRNA is further processed by the endonuclease, Dicer, to generate the small double-stranded miRNA duplex (28). Once formed, the miRNA duplex recruits argonaute protein (AGO) for unwinding (29). A strand of the duplex, namely mature miRNA, associates with the RNA induced silencing complex and mediates mRNA degradation or translational repression by binding to the partially complementary sequences of the 3'-untranslated region of specific mRNAs (30).

Similar to protein-coding genes, miRNAs are subjected to stringent regulation, and transcriptional regulation is a major contributor to the tissue- or development-specific gene expression of miRNAs (31). Furthermore, during the maturation steps, specific RNA binding proteins intricately interact with the processing machineries of a range of miRNAs through functional interactions, which subsequently modulates the expression of their target mRNAs (32). In addition, single nucleotide polymorphisms, RNA editing and methylation are considered important mechanisms that control the expression levels and functions of miRNAs (33).

 3. Triptolide modulates the expression of miRNAs

Recent studies have demonstrated that miRNAs are involved in antitumor, anti-inflammatory and immunosuppressive activities of triptolide (18,20,21,34-37). In addition, triptolide exerts renal protective, cardioprotective and antiangiogenesis functions by regulating the expression of miRNAs (38-42). Furthermore, miRNAs are closely associated with the multiorgan toxicity of triptolide (23,43). Tables I and II list evidence supporting miRNAs as pivotal mediators in the pharmacological properties of triptolide.

<sec> <title>miRNAs involved in the antitumor activity of triptolide

Several miRNAs act as tumor-suppressor genes or oncogenes, and increasing evidence suggest that the suppressive function of triptolide on multiple tumors is mediated by regulating miRNAs (44,45). In human T-cell lymphocytic leukemia cells, triptolide significantly increases miR-16-1 expression and decreases miR-138-2 expression, and downregulation of miR-16-1 expression contributes to triptolide-induced apoptosis (46). Triptolide-induced hepatocellular carcinoma cell death is associated with the suppression of two oncogenic miRNA clusters, miR-17-92 and miR-106b-25(24). In pancreatic cancer cells, treatment with triptolide increases miR-204 expression, which directly binds to myeloid cell leukemia-1 (Mcl-1), an antiapoptotic gene essential for cell survival (47), thereby inhibiting Mcl-1 protein expression and inducing cell-type dependent apoptosis or autophagic cell death (48). In addition, triptolide decreases miR-142-3p expression, which negatively regulates Hsp70 expression, a stress protein recognized as an apoptosis inhibitor (49), and suppresses pancreatic cancer cell proliferation (50). In vivo studies have confirmed that triptolide abrogates human pancreatic tumors xenografts by concurrent upregulation of miR-204 and miR-142-3p expression and downregulation of Mcl-1 or Hsp70 expression, respectively (48,50). In colon carcinoma cells, treatment with triptolide downregulates miR-191 expression, which in turn suppresses cell proliferation and migration, induces apoptosis and activates the nuclear factor kappa-B (NF-κB) and Wnt/β-catenin signaling pathways (34). Notably, these effects were reversed following transfection with miR-191 mimics, suggesting that the anti-colorectal cancer activities of triptolide are associated with the downregulation of miR-191 expression (34). Through upregulation of miR-146a expression, triptolide markedly decreases the expression levels of the RhoA and Rac1 genes in breast cancer cells, which are both key members of the Rho GTPase family involved in tumor invasion and metastasis, and thus act as metastasis suppressors (18). Triptolide also induces S phase cell cycle arrest of human nasopharyngeal carcinoma cells by enhancing p85α-phosphatase and tensin homolog (PTEN) complex formation and inactivating AKT-mediated cyclin-dependent kinase 2 phosphorylation, which requires downregulation of miR-144 expression (35). Triptolide also inhibits the proliferation of nephroblastoma and medulloblastoma cells, and benign prostatic epithelial cells. In addition, triptolide inhibits the migratory ability of these cells but promotes apoptosis by upregulating the expression levels of miR-193b-3p, miR-138 and miR-218 (51-53). The latter activities involving miRNAs corresponded to inactivation of the phosphatidylinositol 3 kinase (PI3K)/AKT and extracellular regulated protein kinase (ERK) signaling pathways by downregulating Kruppel-like factor, inactivating the Notch signaling pathway, as well as suppressing CDK6 expression, or negatively regulating survivin and inactivating the mammalian target of rapamycin (mTOR) signaling pathway, respectively (51-53).

Sequencing data indicate that triptolide markedly alters the expression profiles of miRNAs in human non-small cell lung cancer cells. miRNAs associated with cell motility, such as miR-146a, miR-23b and miR-199b (54-56), are significantly upregulated or downregulated, and subsequent studies have validated that triptolide notably decreases lung cancer cell migration, invasion and metastasis by suppressing focal adhesion kinase expression and disrupting its downstream signaling pathways (25). Furthermore, treatment with triptolide causes a dose-dependent upregulation of miR-204-5p expression, along with decreased expression of its target, SIRT-1, a member of the class III histone deacetylase family required for caveolin-1 (Cav-1) expression (57), thereby coupling Cav-1 downregulation with activation of classical AKT/Bax-mediated apoptosis in non-small cell lung cancer cells (58).

Drug resistance is one of the main reasons for therapy failure in cancer treatment (59). miRNAs are critical regulators of molecular pathways implicated in cancer drug resistance (60). miR-21 is highly expressed and associated with disease progression and multidrug-resistance in different types of cancer (61). Triptolide notably decreases miR-21 expression in non-small cell lung cancer cells, and increases PTEN protein expression, which acts as a tumor suppressor and participates in tumor occurrence and development, and decreases cell proliferation and enhances apoptosis (62). However, ectopic miR-21 expression rescues the effect of triptolide on PTEN protein expression and cell viability, suggesting that triptolide mediates the decrease in miR-21 expression, which in turn promotes cell death by upregulating PTEN expression (62). Furthermore, triptolide significantly enhances adriamycin-induced cytotoxicity by decreasing miR-21 expression and increasing PTEN expression, and reverses drug resistance to human chronic myeloid leukemia cells (63).

In cisplatin-resistant human ovarian cancer cells, upregulation of miR-6751 expression via triptolide decreases hexokinase 2 protein expression, which confers resistance to cisplatin by enhancing autophagic activity, and sensitizes cells to the proapoptotic effect of cisplatin (64). A similar synergistic proapoptotic effect was detected following combined treatment with triptolide and dexamethasone in human multiple myeloma cells, which has the ability to overcome the glucocorticoid resistance of these cells by enhancing glucocorticoid receptor expression by inhibiting miR-142-5p and miR-181a expression (65). Furthermore, miR-181a expression is notably attenuated in osteosarcoma cells following treatment with triptolide, which directly upregulates PTEN expression, whereas transfection with miR-181a mimics restores PTEN expression, and decreases the inhibitory effect of triptolide on osteosarcoma cell proliferation and invasion, suggesting the anti-osteosarcoma properties of triptolide depended on the regulation of miR-181a and its targeting of the PTEN gene (66). Conversely, upregulated miR-181a expression participates in the suppressive effect of triptolide against human neuroblastoma cell proliferation and migration, and via activation of the mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways (67). Thus, triptolide can upregulate or downregulate the expression of specific miRNAs, influence downstream targeting signaling pathways, and thus exert antitumor activities (Fig. 1).

 miRNAs involved in the anti-inflammatory and immunosuppressive activities of triptolide

Several miRNAs are substantially activated by inflammatory stimuli, such as the Toll-like receptor (TLR), ligand lipopolysaccharide (LPS) and components of the inflammatory processes by post-transcriptional regulation of either signal transduction proteins of inflammatory pathways or specific inflammatory cytokines (68). For example, miR-155, which is implicated in the pathogenesis of inflammatory diseases (69), has prompted investigation on the association between triptolide and miR-155 in these inflammatory diseases. cDNA array and northern blot analysis have demonstrated that the expression of inflammatory cytokine, as well as miR-155 are markedly upregulated in macrophages following LPS stimulation, whereas triptolide attenuates the induction of these genes in a dose-dependent manner (70).

Similar observations were obtained in monocytes from patients with rheumatoid arthritis (19), whereby overexpression of miR-155 reverses the inhibitory effect of triptolide on LPS-induced interleukin (IL)-6 and tumor necrosis factor-α production, and antagonizes the effect of triptolide on Src homology 2-containing inositol phosphatase-1 (SHIP-1), which is a target of miR-155 and functions as a potent inhibitor of several inflammatory pathways (71). Thus, it has been proposed that triptolide inhibits miR-155 expression, which negatively affects its downstream target, SHIP-1, and suppresses the inflammatory response stimulated by LPS.

The miR-155/SHIP-1 axis plays a critical role in triptolide-induced improvement on the symptoms of other inflammatory diseases. Inhibiting the miR-155/SHIP-1 axis via triptolide suppresses NF-κB activity via the PI3K/AKT pathway, which significantly inhibits microglial activation and stimulates inflammatory cytokines stimulated by prion-like preformed fibril (20).

Triptolide has also been reported to suppress miR-155 expression and simultaneously promote SHIP-1 expression in the small intestine, particularly in the anastomosis of IL-10 deficient mice subjected to ileocecal resection (72). These effects are also associated with decreased levels of inflammatory cytokines, and eventually exert therapeutic effects on Crohn's disease, an inflammatory bowel disease (72). Studies on Crohn's disease have reported that triptolide effectively reverses upregulated miR-16-1 expression and downregulated Hsp70 expression at the anastomosis sites in IL-10 deficient mice, as well as in patients with Crohn's disease, which represents a protective mechanism against postsurgical inflammation and anastomotic fibrosis (37,73).

With regards to the effects on osteoarthritis, downregulation of miR-20b expression following treatment with triptolide notably upregulates its target inflammasome-related gene, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3, which limits the activation of caspase-1 and subsequently inhibits the maturation of inflammatory cytokines, thus preventing the development of osteoarthritis (41). In the treatment of spinal cord injury (SCI), the anti-inflammatory activity of triptolide is mediated by upregulated miR-96 expression, which inactivates NF-κB by negatively regulating the inhibitor of NF-κB kinase subunit β expression, and decreases inflammatory cytokine levels in LPS-induced primary microglia and spinal cord tissues of SCI rats (42).

Triptolide is frequently used as an immunosuppressive compound in the treatment of chronic autoimmune diseases, including systemic lupus erythematosus (SLE) (12). Recently, a novel miRNA target was identified following treatment of SLE by triptolide. Triptolide was demonstrated to markedly increase miR-125a-5p expression, as well as the percentage of regulatory T cells (Treg), which are important in modulating self-tolerance and autoimmunity (74). Conversely, miR-125a-5p inhibitor significantly abrogates the effects of triptolide on Treg, suggesting that triptolide stimulates Treg activation via miR-125a-5p, and thereby alleviates the clinical and histological symptoms observed in the SLE mouse model (21). Taken together, these findings suggest that changes in the expression levels of specific miRNAs contribute to the anti-inflammatory and immunosuppressive properties of triptolide.

 miRNAs involved in the renal protective and cardioprotective activities of triptolide

Increasing evidence suggest that triptolide exhibits renal protective effects by regulating the expression of miRNAs (22,38,39,75,76). In adriamycin-induced nephropathy rat models, elevated expression levels of miR-344b-3p and miR-30b-3p were observed, the effects of which were reversed following treatment with triptolide. Triptolide also increases the levels of nephrin protein, which is involved in the maintenance of the glomerular filtration barrier structure in the kidney cortex, thereby attenuating podocyte damage and partially improving renal function (76). Thus, it has been speculated that miR-344b-3p and miR-30b-3p are involved in the protective effect of triptolide towards podocytes from adriamycin-induced nephropathy (76). In the transforming growth factor-β (TGF-β)-induced podocyte injury model, the presence of triptolide completely reversed TGF-β-induced miR-30 downregulation, suppressed TGF-β-stimulated activation of downstream damaging pathways, including MAPK, NF-κB and calcineurin/NFATC3, and alleviated podocyte injury in vitro and ex vivo (22).

During the development of diabetic kidney disease (DKD), miRNAs are closely associated with multiple pathological modifications (77). Triptolide notably mitigates the impaired renal function by exerting a therapeutic effect on DKD through the regulation of miRNA-mediated signaling pathways (38,75). For example, triptolide significantly reverses the increase in miR-188-5p expression induced by high glucose in human proximal tubular epithelial cells and diabetic kidneys, which enhances the expression of action target PTEN, and inactivates the downstream PI3K/AKT signaling pathway and inhibits renal epithelial-to-mesenchymal transition in DKD (38). Similarly, downregulation of miR-141-3p expression via triptolide affects the target PTEN protein in human renal mesangial cells, under high glucose, with an opposite tendency. In addition, triptolide-induced autophagic activation and fibrosis alleviation in association with the activation of the PTEN/AKT/mTOR pathway is blocked following overexpression of miR-141-3p (75).

The miR-137/Notch1 pathway prevents glomerulosclerosis under diabetic conditions (39). Unlike miR-188-5p and miR-141-3p, miR-137 expression significantly decreases in high glucose-incubated renal mesangial cells and in diabetic rat kidney tissues, but returns to normal levels following treatment with triptolide (39). Triptolide inactivates the Notch1 pathway reliance on miR-137, which suppresses extracellular matrix protein accumulation of collagen IV and fibronectin, thus improving DKD by protecting against glomerulosclerosis (39).

The cardioprotective activity of triptolide has been attributed to the changes in miR-21 expression. Treatment with triptolide markedly decreases miR-21 expression, inactivates the TLR4/MAPK/NF-κB signaling pathway and prevents cell apoptosis in LPS-treated myocardial cells, as well as in cardiac tissues from adjuvant arthritis rat models (40,41). Collectively, these findings confirm the regulatory role of miRNAs in the renal protective and cardioprotective activities of triptolide.

 miRNAs involved in the antiangiogenesis activity of triptolide

A key feature of atherosclerosis is the dysregulated progression of endothelial cell angiogenesis within the plaques, a process that is regulated by several miRNAs, particularly miR-92a (78). miR-92a blocks angiogenesis both in vitro and in vivo (79), and participates in the inhibitory effect of triptolide in atherosclerosis. In human dermal microvascular endothelial cells, triptolide effectively induces miR-92a expression in a dose-dependent manner, and impedes the production of integrin subunit α 5 (ITGA5), which is a direct target of miR-92a (42). Overexpression of ITGA5 inactivates the ERK and PI3K/AKT signaling pathways, as well as the accumulation of a number of angiogenesis-related factors, such as endothelial nitric oxide synthase, VEGF receptor-2 and VEGF, which inhibits angiogenesis (42). These effects are reversed following ITGA5 knockdown (42). Thus, miR-92a acts as a crucial mediator in the antiangiogenesis activity of triptolide by inactivating the ERK and PI3K/AKT signaling pathways following downregulation of ITGA5 expression.

 miRNAs involved in the multiorgan toxicity of triptolide

Several miRNAs, such as miR-122 and miR-26a, are involved in the multiorgan toxicity observed following treatment with triptolide, and are considered sensitive early warning indicators (80). Oral administration of triptolide in male rats led to cardiac dysfunction and myocardial cell death. These effects were associated with at least a 2-fold increase in the expression levels of 108 miRNAs, as well as a 2-fold decrease in the expression levels of eight miRNAs in heart tissue samples. Furthermore, changes in plasma miRNAs were also detected (81). Among these, 28 miRNAs were predicted to simultaneously regulate the expression of aryl hydrocarbon receptor (AhR), which is a transcription factor that is closely associated with cardiac pathophysiology (81). Another study confirmed that triptolide significantly decreases myocardial and plasma AhR levels, as well as its downstream gene, CYP1A1 (23).

miR-122 expression is significantly upregulated in adult zebrafish or mice livers following treatment with liver toxicants, including acetaminophen or tamoxifen (82). A similar trend has been observed in zebrafish larvae following treatment with triptolide, which causes hepatic injury (83), which is considered to be a crucial event resulting from deregulated hepatic function caused by altered miR-122 expression (84). Taken together, these findings suggest that miR-122 may be used as a diagnostic predictor and an attractive therapeutic target for the hepatotoxicity activity of triptolide.

miR-26a expression is upregulated in triptolide-induced reproductive toxicity in mouse Leydig cells (43). This results in cytotoxicity via inhibition of its downstream target, glycogen synthase kinase-3β, which possesses antiapoptotic effects (43). Collectively, these findings indicate the association between miRNAs and the multiorgan toxicity of triptolide.

 4. Molecular mechanisms underlying regulation of miRNAs by triptolide

The regulation of the expression of miRNAs by triptolide is partly mediated by specific transcription factors. Triptolide has been reported to interfere with TGF-β-induced Smad2/3 phosphorylation and activation, and prevents phosphorylated protein binding to Smad4 and their subsequent translocation to nuclei where they are known to regulate gene expression as transcription factors, and thereby completely restore miR-30 downregulation in podocytes (22). As a multifunctional transcription factor, NF-κB positively and negatively regulates the expression of miRNAs (85). Treatment with triptolide decreases the expression and nuclear accumulation of NF-κB in a dose-dependent manner, accompanied by the differential expression of 23 miRNA genes in lymphocytic leukemic cell lines, suggesting that triptolide-induced cytotoxic effects may occur by inhibiting NF-κB transcriptional activity, and consequently influencing the expression of miRNAs (46). c-Myc also plays a critical role in repressing two oncogenic miRNA clusters by triptolide in hepatocellular carcinoma cells (24). Through direct binding to the E-box element in the promoter region of MCM7, c-Myc transactivates both miR-7-92 and miR-106b-25, which function as oncogenes in cancer initiation and progression (86). Triptolide significantly antagonizes the transcription of these two miRNA clusters by targeting c-Myc, and XPB (also known as ERCC3) is involved in this process (24). XPB is a subunit of general transcription factor TFIIH, which is essential for RNA polymerase II-dependent transcription initiation and nucleotide excision repair (87). It has been reported that triptolide covalently binds to the Cys342 residue of XPB, the largest subunit of the general transcription factor TFIIH (88), and impedes its ATPase activity, inhibiting RNA polymerase II mediated transcription (89). Triptolide also acts as an inhibitor of RNA polymerase II by selectively activating CDK7, and subsequently by triggering proteasome-dependent degradation of hyperphosphorylated Rpb1, which is the largest RNA polymerase II subunit (90). On the other hand, triptolide directly suppresses the recruitment of B-related factor 1 to TFIIIB complex, an essential transcription initiation factor of RNA polymerase III (91), and significantly inhibits RNA polymerase III transcription (92). Based on these observations and the fact that miRNA genes are transcribed by RNA polymerase II or III, it is reasonable to speculate that the inhibition of RNA polymerase II and III mediated general transcription underlies miRNAs regulation by triptolide.

Triptolide may also regulate the expression of miRNAs via an enhancer of zeste homolog 2 (EZH2)-involved mechanism. EZH2, a well-known histone methyltransferase (93), is capable of binding to the promoter regions of miRNAs genes and catalyzing histone H3 trimethylation, resulting in the transcriptional silencing of miRNAs genes (94). It has been proven that EZH2 is a target for triptolide in prostate cancer and multiple myeloma cells (95), and a recent study demonstrated that treatment with triptolide significantly downregulates miR-191 expression in colon carcinoma cells in an EZH2-dependent manner, suggesting a modulatory activity of triptolide on the expression of miRNAs at the epigenetic level (34).

The regulation of miRNAs by triptolide may be ascribed to the autophagy pathway. Autophagy can be modulated by triptolide through multiple machineries and signaling pathways, such as oxidative stress, cytoplasmic calcium and the AKT/mTOR/p70S6K pathway (13). miRNAs also play vital roles in autophagy as they can target autophagy-related genes or other related regulators, and participate in regulating the dynamic process of autophagy (96). Triptolide has been reported to significantly decrease miR-141-3p expression, which directly acts on PTEN, and thereby reverses the induced autophagy in high glucose treated human mesangial cells and in DKD rats (75). Conversely, autophagy selectively regulates miRNA homeostasis, which is activated by promoting autophagy receptor-mediated degradation of miRNA pathway components, including DICER and AGO2, further proving an association between autophagy and miRNAs (97). Although the molecular mechanisms involved in the role of autophagy in triptolide regulation of miRNAs remain unclear, it is possible that autophagy may play a functional role, and the precise molecular targets and regulatory networks remain to be elucidated. Collectively, these findings suggest that the expression of triptolide-regulated miRNAs is mediated by multiple intracellular components and molecular mechanisms.

 5. Conclusions and future perspective

Traditional Chinese medicines have been effectively used to cure various diseases. Thus, investigating the molecular mechanisms underlying their activities is highly warranted. As a biologically active ingredient derived from the Chinese herb, Tripterygium wilfordii Hook F., recent studies have demonstrated that triptolide exerts effects on the expression of a series of endogenous miRNAs, which in turn employ several downstream cellular factors to achieve its multiple pharmacological activities, highlighting miRNAs as critical mediators for triptolide-induced effects (18,20,21,23,34-43). However, determining the exact role of these miRNAs is limited by the in vitro models offered by these studies. Haploid cells are effective tools to study gene function due to having one set of chromosomes (98,99). Thus, prospective studies will aim to use haploid cells to screen novel miRNAs for specific functions following treatment with triptolide, and additional evidence from in vivo experiments will validate the conclusions. In addition, regulation of miRNA expression is usually cell- or tissue-specific, and as precise base pairing between miRNA and their corresponding mRNA targets is not required. A single miRNA may simultaneously target several mRNAs, whereas one mRNA can be regulated by different miRNAs (28,30,33). Triptolide may affect PTEN expression by regulating the expression of several miRNAs, including miR-21 (62,63), miR-181a (66), miR-188-5p (38), miR-144(35), miR-141-3p (75), miR-17-92 and miR-106b-25 clusters (24). miR-21 is a common target when triptolide controls the expression of both TLR4 and PTEN (40,41,62,63). Thus, the intricate complexity and integration of the activity of miRNAs present challenges in identifying their function and regulatory pathways. Supplementary bioinformatics tools may provide integrated analyses of these complicated networks that participate in the pharmacological activities of triptolide. Prospective studies are required to investigate whether miRNAs play roles in other pharmacological activities of triptolide.

In conclusion, specific miRNAs have been identified as primary targets when triptolide displays multiple pharmacological effects. These findings also suggest that triptolide can serve as a novel molecular probe for studying miRNAs. A comprehensive understanding of the regulatory pathways and specific functions of these miRNAs will help determine the underlying molecular mechanisms of triptolide and provide more effective strategies for drug development and disease treatment.

 Acknowledgements

Not applicable.

 Availability of data and materials

Not applicable.

 Authors' contributions

YW conceived and supervised the present study. KZ drafted the initial manuscript. YC, BH, RL and YW reviewed the manuscript for important intellectual content. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References AuyeungKKHanQBKoJKAstragalus membranaceus: A review of its protection against inflammation and gastrointestinal cancersAm J Chin Med4412220162691691110.1142/S0192415X16500014 WangZXiaQLiuXLiuWHuangWMeiXLuoJShanMLinRZouDMaZPhytochemistry, pharmacology, quality control and future research of Forsythia suspensa (Thunb.) Vahl: A reviewJ Ethnopharmacol21031833920182888721610.1016/j.jep.2017.08.040 ShiJFLuoYYLiJXLuoRFChenLLiJZhangJMFuCMResearch progress on anti-tumor effects and mechanisms of triptolide and its combined applicationChina J Chin Mater Med443391339820193160290010.19540/j.cnki.cjcmm.20190610.402 NoelPVon HoffDDSalujaAKVelagapudiMBorazanciEHanMTriptolide and its derivatives as cancer therapiesTrends Pharmacol Sci4032734120193097544210.1016/j.tips.2019.03.002 YanPSunXTriptolide: A new star for treating human malignanciesJ Cancer Res Ther14 (Suppl)S271S27520182997067510.4103/0973-1482.235340 HuangGYuanKZhuQZhangSLuQZhuMShengHYuRLuoGXuATriptolide inhibits the inflammatory activities of neutrophils to ameliorate chronic arthritisMol Immunol10121022020183000723110.1016/j.molimm.2018.06.012 HuangSHLinGJChuCHYuJCChenTWChenYWChienMWChuCCSytwuHKTriptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic micePancreas4244245120132314691910.1097/MPA.0b013e318269d076 ZhengCXChenZHZengCHQinWSLiLSLiuZHTriptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitroKidney Int7459661220081850932210.1038/ki.2008.203 YuHShiLZhaoSSunYGaoYSunYQiGTriptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathwayCardiovasc Toxicol1632533520162639189510.1007/s12012-015-9342-y XiCPengSWuZZhouQZhouJToxicity of triptolide and the molecular mechanisms involvedBiomed Pharmacother9053154120172840292210.1016/j.biopha.2017.04.003 ChenSRDaiYZhaoJLinLWangYWangYA mechanistic overview of triptolide and celestrol, natural products from Tripterygium wilfordii Hook FFront Pharmacol910420182949183710.3389/fphar.2018.00104 YuanKLiXLuQZhuQJiangHWangTHuangGXuAApplication and mechanisms of triptolide in the treatment of inflammatory diseases-a reviewFront Pharmacol10146920193186686810.3389/fphar.2019.01469 WeiYMWangYHXueHQLuanZHLiuBWRenJHTriptolide, A potential autophagy modulatorChin J Integr Med2523324020193017809110.1007/s11655-018-2847-z JinWWangJLiuCPWangHWXuRMStructural basis for pri-miRNA recognition by DroshaMol Cell7842343320203222064510.1016/j.molcel.2020.02.024 OlejniczakMKotowska-ZimmerAKrzyzosiakWStress-induced changes in miRNA biogenesis and functioningCell Mol Life Sci7517719120182871787210.1007/s00018-017-2591-0 DexheimerPJCochellaLMicroRNAs: From mechanism to organismFront Cell Dev Biol840920203258269910.3389/fcell.2020.00409 RupaimooleRSlackFJMicroRNA therapeutics: Towards a new era for the management of cancer and other diseasesNat Rev Drug Discov1620322220172820999110.1038/nrd.2016.246 LiuQWangWLiFYuDXuCHuHTriptolide inhibits breast cancer cell metastasis through inducing the expression of miR-146a, a negative regulator of Rho GTPaseOncol Res271043105020193107241810.3727/096504019X15560124931900 PengAHuangXLiuRWangXZhuangJTriptolide inhibits the inflammatory response of monocytes from rheumatoid arthritis patients by regulating miR-155Chin J Cell Mol Immunol30635638201424909288 FengYZhengCZhangYXingCCaiWLiRChenJDuanYTriptolide inhibits preformed fibril-induced microglial activation by targeting the microRNA155-5p/SHIP1 pathwayOxid Med Cell Longev2019652763820193118299610.1155/2019/6527638 ZhaoXTangXYanQSongHLiZWangDChenHSunLTriptolide ameliorates lupus via the induction of miR-125a-5p mediating Treg upregulationInt Immunopharmacol71142120193086139310.1016/j.intimp.2019.02.047 YangQSunMChenYLuYYeYSongHXuXShiSWangJTriptolide protects podocytes from TGF-β-induced injury by preventing miR-30 downregulationAm J Transl Res951505159201729218112 WangSRChenXLingSNiRZGuoHXuJWMicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in ratsBiomed Pharmacother1111467147720193084146210.1016/j.biopha.2018.12.109 LiSGShiQWYuanLYQinLPWangYMiaoYQChenZLingCQQinWXC-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cellsJ Exp Clin Cancer Res375120182952315910.1186/s13046-018-0698-2 RenoTAKimJYRazDJTriptolide inhibits lung cancer cell migration, invasion, and metastasisAnn Thorac Surg1001817182520152629816810.1016/j.athoracsur.2015.05.074 KallaRVenthamNTKennedyNAQuintanaJFNimmoERBuckAHSatsangiJMicroRNAs: New players in IBDGut6450451720152547510310.1136/gutjnl-2014-307891 MichlewskiGCaceresJFPost-transcriptional control of miRNA biogenesisRNA2511620193033319510.1261/rna.068692.118 SaliminejadKKhorram KhorshidHRSoleymani FardSGhaffariSHAn overview of microRNAs: Biology, functions, therapeutics, and analysis methodsJ Cell Physiol2345451546520193047111610.1002/jcp.27486 VishnoiARaniSmiRNA biogenesis and regulation of diseases: An overviewMethods Mol Biol150911020172782691210.1007/978-1-4939-6524-3_1 YatesLANorburyCJGilbertRJThe long and short of microRNACell15351651920132362223810.1016/j.cell.2013.04.003 TurnerMJSlackFJTranscriptional control of microRNA expression in C elegans: Promoting better understandingRNA Biol6495320091910663010.4161/rna.6.1.7574 KeddeMStrasserMJBoldajipourBOude VrielinkJASlanchevKle SageCNagelRVoorhoevePMvan DuijseJOromUARNA-binding protein Dnd1 inhibits microRNA access to target mRNACell1311273128620071815513110.1016/j.cell.2007.11.034 KrolJLoedigeIFilipowiczWThe widespread regulation of microRNA biogenesis, function and decayNat Rev Genet1159761020102066125510.1038/nrg2843 QiYLiJTriptolide inhibits the growth and migration of colon carcinoma cells by down-regulation of miR-191Exp Mol Pathol107233120193068446210.1016/j.yexmp.2019.01.008 WuCWWangSGLinMLChenSSDownregulation of miR-144 by triptolide enhanced p85α-PTEN complex formation causing S phase arrest of human nasopharyngeal carcinoma cellsEur J Pharmacol85513714820193105971110.1016/j.ejphar.2019.04.052 ChenMWangJMWangDWuRHouHWTriptolide inhibits migration and proliferation of fibroblasts from ileocolonic anastomosis of patients with Crohn's disease via regulating the miR161/HSP70 pathwayMol Med Rep194841485120193094242310.3892/mmr.2019.10117 QianKZhangLShiKTriptolide prevents osteoarthritis via inhibiting hsa-miR-20bInflammopharmacology2710911920192997431010.1007/s10787-018-0509-6 XueMChengYHanFChangYYangYLiXChenLLuYSunBChenLTriptolide attenuates renal tubular epithelial-mesenchymal transition via the miR-188-5p-mediated PI3K/AKT pathway in diabetic kidney diseaseInt J Biol Sci141545155720183026300710.7150/ijbs.24032 HanFWangSChangYLiCYangJHanZChangBSunBChenLTriptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathwayJ Cell Physiol2332225223720182869598410.1002/jcp.26092 CaoYGuoYWangYCaoYZongRHuangCLiuJDrug-containing serum of Xinfeng capsules protect against H9C2 from death by enhancing miRNA-21 and inhibiting toll-like receptor 4/phosphorylated p-38 (p-p38)/p-p65 signaling pathway and proinflammatory cytokines expressionJ Tradit Chin Med38359365201832185967 CaoYXHuangDLiuJZongRKWanLHuangCBZhangWDWangYA novel chinese medicine, xinfeng capsule, modulates proinflammatory cytokines via regulating the toll-like receptor 4 (TLR4)/Mitogen-activated protein kinase (MAPK)/Nuclear Kappa B (NF-κB) signaling pathway in an adjuvant arthritis rat modelMed Sci Monit256767677420193149582710.12659/MSM.916317 XuXTianLZhangZTriptolide inhibits angiogenesis in microvascular endothelial cells through regulation of miR-92aJ Physiol Biochem7557358320193169116210.1007/s13105-019-00707-2 LiangHZhangSLiZGinsenoside Rg3 protects mouse leydig cells against triptolide by downregulation of miR-26aDrug Des Devel Ther132057206620193129698410.2147/DDDT.S208328 MamooriAGopalanVLamAKRole of miR-193a in cancer: Complexity and factors control the patterns of its expressionCurr Cancer Drug Targets1861862820182952123210.2174/1568009618666180308105727 SvoronosAAEngelmanDMSlackFJOncomiR or tumor suppressor? The duplicity of microRNAs in cancerCancer Res763666367020162732564110.1158/0008-5472.CAN-16-0359 MengHTZhuLNiWMYouLSJinJQianWBTriptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kappaB activity and miR-16-1*Acta Pharmacol Sin3250351120112144194810.1038/aps.2010.237 XiangWYangCYBaiLMcl-1 inhibiton in cancer treatmentOnco Targets Ther117301731420183042552110.2147/OTT.S146228 ChenZSangwanVBanerjeeSMackenzieTDudejaVLiXWangHVickersSMSalujaAKmiR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell deathMol Cancer1210520132402518810.1186/1476-4598-12-105 RoufayelRKadrySMolecular chaperone HSP70 and key regulators of apoptosis - a reviewCurr Mol Med1931532520193091402410.2174/1566524019666190326114720 MacKenzieTNMujumdarNBanerjeeSSangwanVSarverAVickersSSubramanianSSalujaAKTriptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferationMol Cancer Ther121266127520132363565210.1158/1535-7163.MCT-12-1231 HangSWangXLiHTriptolide inhibits viability and migration while promotes apoptosis in nephroblastoma cells by regulation of miR-193b-3pExp Mol Pathol108808820193097833310.1016/j.yexmp.2019.04.006 ZhangHLiHLiuZGeAGuoELiuSChenZTriptolide inhibits the proliferation and migration of medulloblastoma Daoy cells by upregulation of microRNA-138J Cell Biochem1199866987720183015600910.1002/jcb.27307 YaoCLiHZhangWTriptolide inhibits benign prostatic epithelium viability and migration and induces apoptosis via upregulation of microRNA-218Int J Immunopathol Pharmacol32205873841881234920183045379910.1177/2058738418812349 LiuQWangWYangXZhaoDLiFWangHmiRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancerOncol Rep3618919620162717594110.3892/or.2016.4788 HuHTangJLiuCCenYmiR-23b promotes the migration of keratinocytes through downregulating TIMP3J Surg Res25410210920203242242910.1016/j.jss.2020.03.043 WangJZhouFYinLZhaoLZhangYWangJMicroRNA-199b targets the regulation of ZEB1 expression to inhibit cell proliferation, migration and invasion in non-small cell lung cancerMol Med Rep165007501420172884901810.3892/mmr.2017.7195 CharlesSRajVArokiarajJMalaKCaveolin1/protein arginine methyltransferase1/sirtuin1 axis as a potential target against endothelial dysfunctionPharmacol Res11911120172812651010.1016/j.phrs.2017.01.022 PhilipsBJKumarABurkiSRyanJPNodaKD'CunhaJTriptolide-induced apoptosis in non-small cell lung cancer via a novel miR204-5p/Caveolin-1/Akt-mediated pathwayOncotarget112793280620203273364910.18632/oncotarget.27672 CaoYAdipocyte and lipid metabolism in cancer drug resistanceJ Clin Invest1293006301720193126496910.1172/JCI127201 GomesBCRueffJRodriguesASMicroRNAs and cancer drug resistanceMethods Mol Biol139513716220162691007310.1007/978-1-4939-3347-1_9 PfefferSRYangCHPrefferLMThe role of miR-21 in cancerDrug Dev Res7627027720152608219210.1002/ddr.21257 LiXZangAJiaYZhangJFanWFengJDuanMZhangLHuoRJiaoJZhuXTriptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21Mol Med Rep132763276820162684760110.3892/mmr.2016.4844 LiHHuiLXuWShenHChenQLongLZhuXTriptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expressionPharm Biol501233124020122295779210.3109/13880209.2012.665931 WangRMaXSuSLiuYTriptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751Future Med Chem101947195520182996644110.4155/fmc-2018-0108 HuangXYangMJinJTriptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAsLeuk Lymphoma531188119520122226016310.3109/10428194.2011.638069 JiangCFangXZhangHWangXLiMJiangWTianFZhuLBianZTriptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitroTumour Biol39101042831769755620172838115810.1177/1010428317697556 JiangJSongXYangJLeiKNiYZhouFSunLTriptolide inhibits proliferation and migration of human neuroblastoma SH-SY5Y cells by upregulating MicroRNA-181aOncol Res261235124320182942637510.3727/096504018X15179661552702 O'ConnellRMRaoDSBaltimoreDmicroRNA regulation of inflammatory responsesAnnu Rev Immunol3029531220122222477310.1146/annurev-immunol-020711-075013 MaheshGBiswasRmiRNA-155: A master regulator of inflammationJ Interferon Cytokine Res3932133020193099842310.1089/jir.2018.0155 MattaRWangXGeHRayWNelinLDLiuYTriptolide induces anti-inflammatory cellular responsesAm J Transl Res1267282200919956437 TangHMaoJYeXZhangFKerrWGZhengTZhuZSHIP-1, a target of miR-155, regulates endothelial cell responses in lung fibrosisFASEB J342011202320203190799710.1096/fj.201902063R WuRLiYGuoZGongJZhuWLiNLiJTriptolide ameliorates ileocolonic anastomosis inflammation in IL-10 deficient mice by mechanism involving suppression of miR-155/SHIP-1 signaling pathwayMol Immunol5634034620132391138810.1016/j.molimm.2013.05.006 HouHWWangJMWangDWuRJiZLTriptolide exerts protective effects against fibrosis following ileocolonic anastomosis by mechanisms involving the miR-16-1/HSP70 pathway in IL-10-deficient miceInt J Mol Med4033734620172862759210.3892/ijmm.2017.3016 LeeGRThe balance of Th17 versus Treg cells in autoimmunityInt J Mol Sci1973020182951052210.3390/ijms19030730 LiXYWangSSHanZHanFChangYPYangYXueMSunBChenLMTriptolide restores autophagy to alleviate diabetic renal fibrosis through the miR-141-3p/PTEN/Akt/mTOR pathwayMol Ther Nucleic Acids9485620172924632310.1016/j.omtn.2017.08.011 JiangCBWeiMGTuYZhuHLiCQJingWMSunWTriptolide attenuates podocyte injury by regulating expression of miRNA-344b-3p and miRNA-30b-3p in rats with adriamycin-induced nephropathyEvid Based Complement Alternat Med201510781420152607876610.1155/2015/107814 IgnarskiMIslamRMullerRULong non-coding RNAs in kidney diseaseInt J Mol Sci20327620193127730010.3390/ijms20133276 BonauerACarmonaGIwasakiMMioneMKoyanagiMFischerABurchfieldJFoxHDoebeleCOhtaniKMicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in miceScience3241710171320091946096210.1126/science.1174381 ZhangLZhouMQinGWeintraubNLTangYmiR-92a regulates viability and angiogenesis of endothelial cells under oxidative stressBiochem Biophys Res Commun44695295820142465066610.1016/j.bbrc.2014.03.035 MarroneAKBelandFAPogribnyIPThe role for microRNAs in drug toxicity and in safety assessmentExpert Opin Drug Metab Toxicol1160161120152573931410.1517/17425255.2015.1021687 IchiharaSLiPMiseNSuzukiYIzuokaKNakajimaTGonzalezFIchiharaGAblation of aryl hydrocarbon receptor promotes angiotensin II-induced cardiac fibrosis through enhanced c-Jun/HIF-1α signalingArch Toxicol931543155320193101636210.1007/s00204-019-02446-1 NamHSHwangKSJeongYMRyuJIChoiTYBaeMASonWCYouKHSonHYKimCHExpression of miRNA-122 induced by liver toxicants in ZebrafishBiomed Res Int2016147357820162756366210.1155/2016/1473578 VliegenthartADBWeiCBuckleyCBerendsCde PotterCMJSchneemannSDel PozoJTuckerCMullinsJJWebbDJDearJWCharacterization of triptolide-induced hepatotoxicity by imaging and transcriptomics in a novel Zebrafish modelToxicol Sci15938039120172896252210.1093/toxsci/kfx144 ChengBZhuQLinWWangLMicroRNA-122 inhibits epithelial-mesenchymal transition of hepatic stellate cells induced by the TGF-β1/Smad signaling pathwayExp Ther Med1728429020193065179310.3892/etm.2018.6962 YuanYTongLWuSmicroRNA and NF-kappa BAdv Exp Med Biol88715717020152666299110.1007/978-3-319-22380-3_9 IchikawaDKomatsuSKonishiHOtsujiECirculating microRNA in digestive tract cancersGastroenterology14210741078e107120122243339210.1053/j.gastro.2012.03.008 TitovDVGilmanBHeQLBhatSLowWKDangYSmeatonMDemainALMillerPSKugelJFXPB, a subunit of TFIIH, is a target of the natural product triptolideNat Chem Biol718218820112127873910.1038/nchembio.522 ChauhanAKLiPSunYWaniGZhuQWaniAASpironolactone-induced XPB degradtion requires TFIIH integrity and ubiquitin-selective segregase VCP/p97Cell Cycle20819520213338199710.1080/15384101.2020.1860559 HeQLTitovDVLiJTanMYeZZhaoYRomoDLiuJOCovalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolideAngew Chem Int Ed Engl541859186320152550462410.1002/anie.201408817 ManzoSGZhouZLWangYQMarinelloJHeJXLiYCDingJCapranicoGMiaoZHNatural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase IICancer Res725363537320122292655910.1158/0008-5472.CAN-12-1006 Abascal-PalaciosGRamsayEPBeuronFMorrisEVanniniAStructural basis of RNA polymerase III transcription initiationNature55330130620182934563710.1038/nature25441 LiangXXieRSuJYeBWeiSLiangZBaiRChenZLiZGaoXInhibition of RNA polymerase III transcription by Triptolide attenuates colorectal tumorigenesisJ Exp Clin Cancer Res3821720193112228410.1186/s13046-019-1232-x YamagishiMUchimaruKTargeting EZH2 in cancer therapyCurr Opin Oncol2937538120172866581910.1097/CCO.0000000000000390 IhiraKDongPXiongYWatariHKonnoYHanleySJNoguchiMHirataNSuizuFYamadaTEZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axisOncotarget8135091352020172808878610.18632/oncotarget.14586 TamgueOChaiCSHaoLZambeJCHuangWWZhangBLeiMWeiYMTriptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cellsAsian Pac J Cancer Prev145663566920132428955910.7314/apjcp.2013.14.10.5663 AkkocYGozuacikDMicroRNAs as major regulators of the autophagy pathway. Biochim Biophys Acta Mol Cell Res 1867: Kappa B, 2020. GibbingsDMostowySJayFSchwabYCossartPVoinnetOSelective autophagy degrades DICER and AGO2 and regulates miRNA activityNat Cell Biol141314132120122314339610.1038/ncb2611 PengKLiXWuCWangYYuJZhangJGaoQZhangWZhangQFanYDerivation of haploid trophoblast stem cells via conversion in vitroiScience1150851820193063521510.1016/j.isci.2018.12.014 WangHZhangWYuJWuCGaoQLiXLiYZhangJTianYTanTGenetic screening and multipotency in rhesus monkey haploid neural progenitor cellsDevelopment145dev16053120182978467210.1242/dev.160531 HuangYZhuNChenTChenWKongJZhengWRuanJTriptolide suppressed the microglia activation to improve spinal cord injury through miR-96/IKKβ/NF-κB pathwaySpine (Phila Pa 1976)44E707E71420193115036810.1097/BRS.0000000000002989

miRNAs involved in the antitumor activity of triptolide. Through upregulation and downregulation of specific miRNAs, triptolide affects downstream signaling pathways, which induces tumor cell cycle arrest, interferes with cell proliferation, suppresses cell migration, invasion and metastasis, enhances cell death and reverses drug resistance. miRNA, microRNA; PTEN, phosphatase and tensin homolog; CDK, cyclin-dependent kinase; Hsp, heat shock protein; EZH2, enhancer of zeste homolog 2; NF-κB, nuclear factor kappa-B; PI3K, phosphatidylinositol 3 kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; KLF4, Kruppel-like factor; ERK, extracellular regulated protein kinase; Cav-1, caveolin-1; HK2, hexokinase 2; GR, glucocorticoid receptor.

Triptolide modulates the expression of miRNAs in vitro.

miRNAs Triptolide dosage and treatment time Cell lines miRNA status Downstream targets Related biological effects Refs.
miR-16-1 80 nmol/l, 3, 6 or 12 h; 20, 40 or 80 nmol/l, 8 h Human T-cell lymphocytic leukemia cell line, Molt-4 ↓ Not mentioned Apoptosis↑ (46)
miR-16-1 20, 40 or 80 nmol/l, 8 h Human T-cell lymphocytic leukemia cell line, Jurkat ↓ Not mentioned Not mentioned (46)
miR-138-2 80 nmol/l, 3, 6 or 12 h; 20, 40 or 80 nmol/l, 8 h Human T-cell lymphocytic leukemia cell line, Molt-4 ↑ Not mentioned Not mentioned (46)
miR-138-2 20, 40 or 80 nmol/l, 8 h Human T-cell lymphocytic leukemia cell line, Jurkat ↑ Not mentioned Not mentioned (46)
miR-17-92, miR-106b-25 clusters 200 nmol/l, 24 h Human liver cancer cell line, HepG2 ↓ PTEN and BIM BIM and PTEN↑; apoptosis↑ (24)
miR-204 100 nmol/l, 24 h Human pancreatic cancer cell line, MIA PaCa-2 ↑ Mcl-1 Mcl-1↓; apoptosis↑ (48)
miR-204 100 nmol/l, 24 h Human pancreatic cancer cell line, S2-VP10 ↑ Mcl-1 Mcl-1↓; autophagic cell death↑ (48)
miR-142-3p 100 nmol/l, 24 h Human pancreatic cancer cells lines, MIA PaCa-2, Capan-1 and S2-013 ↑ Hsp70 Hsp70↓; cell proliferation↓ (50)
miR-191 50 or 100 nmol/l, 24 h Human colorectal cancer cell lines, HT-29 and SW480 ↓ Not mentioned EMT↓; NF-κB and Wnt/β-catenin pathways↓; cell proliferation↓; migration↓; apoptosis↑ (34)
miR-146a 15 ng/ml, 24 h Human breast cancer cell line, MDA-MB-231 ↑ Rac1; RhoA RhoA and Rac1↓; cell invasion and metastasis↓ (18)
miR-144 40 nmol/l, 36 h Human nasopharyngeal carcinoma cell lines, NPC-TW039 and NPC-TW076 ↓ PTEN PTEN↑; p85α–PTEN complex↑; p-CDK2↓; S phase arrest (35)
miR-193b-3p 25 nmol/l, 72 h Human malignant rhabdoid kidney tumor cell line, G-401 ↑ KLF4 KLF4↓; PI3K/AKT and ERK signaling pathways↓; cell viability↓; cell migration↓; apoptosis↑ (51)
miR-193b-3p 10, 25 or 50 nmol/l, 72 h Human malignant rhabdoid kidney tumor cell line, WiT49 ↑ Not mentioned Not mentioned (51)
miR-138 100 nmol/l, 24 h Human medulloblastoma cell line, Daoy ↑ CDK6 CDK6↓; PI3K/AKT and Notch signaling pathways↓; cell proliferation↓; cell migration↓; apoptosis↑ (52)
miR-218 100 nmol/l, 24 h Human benign prostatic hypertrophy epithelial cell line, BPH-1 ↑ Survivin Survivin↓; mTOR signaling pathway↓; apoptosis↑ (53)
miR-215, miR-146a, miR-199b, miR-449a, miR-190b 10 nmol/l, 48 h Human non-small cell lung cancer cell line, H460 ↑ Not mentioned FAK↓; p-FAK, p-Src, p-p130Cas↓; p-ERK1/2, MMP14↑; cell migration, invasion and metastasis↓ (25)
miR-92a, miR-222, miR-23b, miR-27a, miR-25, miR-296 10 nmol/l, 48 h Human non-small cell lung cancer cell line, H460 ↓ Not mentioned FAK↓; p-FAK, p-Src, p-p130Cas↓; p-ERK1/2, MMP14↑; cell migration, invasion and metastasis↓ (25)
miR-204-5p 50 or 100 nmol/l, 20 h Human non-small cell lung cancer cell line, A549 ↑ Sirt-1 Sirt-1↓, Cav-1↓; apoptosis↑ (58)
miR-21 25 or 50 nmol/l, 48 h Human non-small cell lung cancer cell line, PC-9 ↓ PTEN PTEN↑; cell viability↓ (62)
miR-21 5 nmol/l, 72 h Human multidrug-resistant chronic myeloid leukemia cell line, K562/A02 ↓ PTEN PTEN↑; adriamycin resistance↓ (63)
miR-6751 100 nmol/l, 24 h Cisplatin-resistant human ovarian cancer cell line, A2780/CP70 ↑ HK2 HK2↓; apoptosis↑; cisplatin resistance↓ (64)
miR-142-5p and miR-181a 10 ng/ml, 24 h Dexamethasone-treated human multiple myeloma cell line, MM.1S ↓ GR GR↑; dexamethasone resistance↓ (65)
miR-181a 150 nmol/l, 24 h Human osteosarcoma cell lines, SAOS2 and U2OS ↓ PTEN PTEN↑; cell proliferation↓; apoptosis↑; cell invasion↓ (66)
miR-181a 20 nmol/l, 24 h Human neuroblastoma cell line, SH-SY5Y ↑ Not mentioned MAPK and NF-kB signaling pathways↑; cell proliferation↓; apoptosis↑; cell migration↓ (67)
miR-155 0.05, 0.1 or 0.5 µmol/l, 0.5 h LPS-stimulated murine macrophage cell line, RAW264.7 ↓ Not mentioned Proinflammatory cytokines (TNF-α, IL1β, and IL-6) ↓ (70)
miR-155 15 nmol/l, 24 h LPS-stimulated monocytes of patients with rheumatoid arthritis ↓ SHIP-1 SHIP-1↑; proinflammatory cytokines (TNF-α, IL-6)↓ (19)
miR-155 40 nmol/l, 12 h Human wild-type αSyn preformed fibrils-treated mouse primary microglia ↓ SHIP-1 SHIP-1↑; PI3K/AKT signaling pathway↓; NF-κB activity↓; proinflammatory cytokines (TNFα and IL-1β)↓ (20)
miR-16-1 20 ng/ml, 24 h Human primary intestinal fibroblasts from strictured anastomosis tissue ↓ Hsp70 Hsp70↑; cell migration↓; cell proliferation↓; extracellular matrix-associated proteins (Col-I, Col-III and α-SMA)↓ (36)
miR-20b 20 ng/ml, 1 h LPS- and ATP-treated human monocytic cell line, THP-1 ↓ NLRP3 NLRP3↑; cleaved caspase-1↓; proinflammatory cytokines (IL-1β and TNF-α)↓ (37)
miR-96 12.5 nmol/l, 24 h LPS-treated murine microglial cell line, BV2 ↑ IKKβ IKKβ↓; Iba-1↓; proinflammatory cytokines (TNF-α and IL-1β)↓ (100)
miR-96 10 nmol/l, 0.5 h LPS-treated rat primary microglia ↑ Not mentioned Iba-1↓; NF-κB signaling pathway↓; proinflammatory cytokines (TNF-α and IL-1β)↓ (100)
miR-125a-5p 10 nmol/l, 3 days Splenocytes of B6 mice ↑ Not mentioned Foxp3↑; Treg proportion↑ (21)
miR-125a-5p 0.2 mg/kg/day, 91 days Splenocytes of MRL/lpr mice ↑ Not mentioned Foxp3↑; Treg proportion↑ (21)
miR-30 10 ng/ml, 24 h TGF-β-treated immortalized human podocyte cell line ↑ Not mentioned Cell injury mediators (MAPK, NF-κB and NFATC3)↓ (22)
miR-188-5p 5 ng/ml, 48 h High glucose-treated human proximal tubular epithelial cell line, HK-2 ↓ PTEN PTEN↑; PI3K/AKT signaling pathway↓; renal EMT↓ (38)
miR-141-3p 10 µmol/l, 48 h High glucose-treated human mesangial cell ↓ PTEN PTEN↓; autophagy↑; AKT/mTOR signaling pathway↓; diabetic renal fibrosis↓ (75)
miR-137 10 µg/l, 48 h High glucose-treated human renal mesangial cell ↑ Notch1 Notch1 signaling pathway↓; extracellular matrix proteins (Col IV and FN)↓ (39)
miR-21 10 ng/ml, 24 h Rat myocardial cell line, H9C2 ↓ TLR4 TLR4↓; MAPK/NF-κB signaling pathway↓; proinflammatory cytokines (TNF-α, IL-6, and IL-17)↓ (40)
miR-92a 3 µmol/l, 12 h Human dermal microvascular endothelial cell line, HMEC-1 ↑ Integrin subunit alpha 5 (ITGA5) Angiogenic mediators (eNOS, VEGFR2 and VEGF)↓; ITGA5↓; ERK and PI3K/AKT signaling pathways↓ (42)
miR-26a 120 nmol/l, 24 h Mouse Leydig cell line MLTC-1 ↑ GSK3β GSK3β↓; apoptosis↑ (43)

miRNA/miR, microRNA; ↑, upregulation; ↓, downregulation; PTEN, phosphatase and tensin homolog; Mcl-1, myeloid cell leukemia-1; Hsp70, heat shock protein 70; EMT, epithelial-to-mesenchymal transition; NF-κB, nuclear factor kappa-B; CDK2, cyclin-dependent kinase 2; KLF4, Kruppel-like factor; PI3K, phosphatidylinositol 3 kinase; AKT, protein kinase B; ERK, extracellular regulated protein kinase; mTOR, mammalian target of rapamycin; FAK, focal adhesion kinase; MMP14, matrix metalloprotease 14; Cav-1, caveolin-1; HK2, hexokinase 2; GR, glucocorticoid receptor; MAPK, mitogen-activated protein kinase; SHIP-1, Src homology 2-containing inositol phosphatase-1; Col I, collagen I; α-SMA, α-smooth muscle actin; LPS, lipopolysaccharide; NLRP3, nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3; IKKβ, inhibitor of nuclear factor kappa B kinase subunit β; Treg, regulatory T cells; FN, fibronectin; TLR4, Toll-like receptor 4; eNOS, endothelial nitric oxide synthase; VEGFR2, vascular endothelial growth factor receptor-2; ITGA5, integrin subunit α 5; GSK3β, glycogen synthase kinase-3β.

Triptolide modulates the expression of miRNAs in vivo.

miRNAs Triptolide dosage and treatment time Tissue type miRNA status Downstream targets Related biological effects Refs.
miR-17-92; miR-106b-25 clusters 0.2 mg/kg/day, 14 days Xenografted hepatocellular carcinoma from BALB/c nude mice ↓ Not mentioned Tumor volume↓; apoptosis↑ (24)
miR-204 0.42 mg/kg/day, 7 days Xenografted human pancreatic ductal adenocarcinoma from SCID mice ↑ Mcl-1 Mcl-1↓; tumor volume↓ (48)
miR-142-3p 0.42 mg/kg/day, 7 days Xenografted human pancreatic ductal adenocarcinoma from SCID mice ↑ Hsp70 Hsp70↓ (50)
miR-191 0.1, 0.3 or 1 mg/kg/day, 28 days Xenografted human colon carcinoma from BALB/c nude mice ↓ Not mentioned Tumor volume and weight↓ (34)
miR-155 0.07 mg/kg every 2 days, 56 days Small intestinal of IL-10 deficient mice performed ileocecal resection ↓ SHIP-1 SHIP-1↑; anastomosis inflammation score↓; MPO and calprotectin↓; inflammatory cytokines TGF-β ↑, IFN-γ and IL-4, IL-17 ↓ (72)
miR-16-1 0.07 mg/kg every 2 days, 56 days Small intestinal of IL-10 deficient mice performed ileocecal resection ↓ Hsp70 Hsp70↑; anastomosis inflammation score↓; CD4+ cell infiltration area↓; fibrosis score↓; extracellular matrix-associated proteins (collagen, procollagen I and III)↓; inflammatory cytokines (TGF-β1, IL-6 and TNF-α)↓ (73)
miR-96 0.1 mg/kg/day, 10 days Spinal cord of spinal cord injury rat ↑ Not mentioned Iba-1↓; NF-κB pathway↓; inflammatory cytokines (TNF-α and IL-1β)↓ (100)
miR-344b-3p; miR-30b-3p 200 µg/kg/day, 56 days Rat renal cortex with adriamycin- induced nephropathy ↓ Not mentioned Nephrin↑; proteinuria↓; renal pathological lesions↓ (76)
miR-30a 10 ng/ml, 24 h TGF-β1-treated isolated glomeruli of mouse or rats ↑ Not mentioned Not mentioned (22)
miR-188-5p 200 µg/kg/day, 84 days Diabetic rat kidney ↓ PTEN PTEN↑; renal EMT↓; PI3K/AKT signaling pathway↓ (38)
miR-137 100 µg/kg/day, 84 days Diabetic rat kidney ↑ Not mentioned Extracellular matrix proteins (Col IV and FN)↓; Notch1 signaling pathway↓ (39)
miR-21 0.4 mg/kg every 7 days, 28 days Adjuvant arthritis rat cardiac tissue ↓ TLR4 TLR4↓; apoptosis↓; proinflammatory cytokines (TNF-a, IL-6, and IL-17)↓; MAPK/NF-κB signaling pathway↓ (41)
miR-546, miR-343, 108 miRNAs 0.1 mg/kg, single oral dose, 14 days Left ventricular tissue from rats ↑ Not mentioned Regulation of cell adhesion, cell cycling, action potential, cell-cell communication, and DNA binding (23)
miR-384-3p, miR-384-5p, 8 miRNAs 0.1 mg/kg, single oral dose, 14 days Left ventricular tissue from rats ↓ Not mentioned Regulation of calmodulin activity, heterodimerization activity, and signal transduction (23)
miR-483-3p 0.1 mg/kg, single oral dose, 14 days Left ventricular tissue from rats ↑ AhR AhR↓; CYP1A1↓ (23)
miR-15a-3p, miR-615, miR-4833p, miR-127-5p 0.1 mg/kg, single oral dose, 14 days Plasma from rats ↑ Not mentioned Not mentioned (23)
miR-122 0.2, 0.4 or 0.8 µmol/l, 48 h Zebrafish larvae ↑ Not mentioned Histology score of hepatocyte vacuolation, hepatocyte disarray and oncotic necrosis↑; liver volume↓ (83)

miRNA/miR, microRNA; ↑, upregulation; ↓, downregulation; Mcl-1, myeloid cell leukemia-1; Hsp70, heat shock protein 70; SHIP-1, Src homology 2-containing inositol phosphatase-1; MPO, myeloperoxidase; NF-κB, nuclear factor kappa-B; PTEN, phosphatase and tensin homolog; EMT, epithelial-to-mesenchymal transition; Col IV, collagen IV; FN, fibronectin; TLR4, Toll-like receptor 4; MAPK, mitogen-activated protein kinase; AhR, aryl hydrocarbon receptor.